Avergen Pharmaceuticals GmbH is a pre-startup pharma company developing new drug target and therapies for the treatment of neurodegeneration, mental disorders, and other nervous system disorders.
Avergen Pharmaceuticals GmbH
Avergen is conducting drug screening programs in collaboration with research laboratories at the IZB in Martinsried, Germany and at the SBC (Stevenage Bioscience Catalyst),, United Kindom.[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”” connections=”true” suffix=””]
July 2017, Avergen and BioSolveIT win PERMIDES grant to conduct collaboration in the very challenging field of protein-protein interactions (PPIs).
Avergen Pharmaceuticals is supported by grants of the Bayern Innovativ Fund founded by the Bavarian State Government and is located in Nuremberg, Bavaria. The fund supports projects in areas with a high potential for future innovations.